ArticleHealth affairs (Project Hope)2022
Buprenorphine Treatment: Advanced Practice Nurses Add Capacity.
Article in Health affairs (Project Hope), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Nurse Practitioner Conceptions of Capability Providing Medication and Safe Supply for Opioid Use Disorder in Primary Care: A Phenomenographic Study.Journal of advanced nursing · 2025Article
- The Effect of Federal Policy Changes on Buprenorphine Prescribing in Massachusetts.Journal of the American College of Emergency Physicians open · 2025Article
- A qualitative exploration of the use of telehealth for opioid treatment: Implications for nurse-managed care.Journal of clinical nursing · 2024Article
- Growing importance of high-volume buprenorphine prescribers in OUD treatment: 2009-2018.Drug and alcohol dependence · 2024Observational
- Trends in the Prescribing of Buprenorphine for Opioid Use Disorder, 2019-2023.Mayo Clinic proceedings. Innovations, quality & outcomes · 2024Article
- Changes in Buprenorphine Prescribing in Community Health Centers.JAMA health forum · 2024Article
- Perspectives on APRN prescribing of medications for opioid use disorder: Key barriers remain.Journal of substance use and addiction treatment · 2024Article
- Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach.Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing · 2023Article
- Impact of Stigma on Clinician Training for Opioid Use Disorder Care: A Qualitative Study in a Primary Care Learning Collaborative.Annals of family medicine · 2023Article
Corrections and comments
- Erratum issuedErratum.2024
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
During the COVID-19 pandemic, there was slower growth in the number of new waivers authorizing clinicians to provide buprenorphine treatment for opioid use disorder. However, treatment capacity grew at a stable rate as a result of already authorized clinicians obtaining waivers for larger patient panels. Advanced practice nurses accounted for the largest portion of capacity growth during the pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.